A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity
© 2018 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University..
The potential side effects of cabazitaxel (CBZ) in the field of cancer treatment have become a great limitation to its further clinical application. Liposomal delivery is a well-established approach to increase the therapeutic index of hydrophobic drugs. In this study, a PEG-modified liposome was developed for efficiently encapsulating CBZ, thus enhancing its specific tumor inhibition effect and reducing the systemic toxicity. It was found that the loading efficiency of CBZ into the liposome could be improved with the increase of lipophilic materials, as it could be over 80% under the weight ratio of 20:1 (total lipid: CBZ). The diameter of CBZ loaded liposome (CBZLipo) was ∼100 nm. And the liposome suspending in aqueous medium was stable at 4 °C for at least one month, according to the change of its size distribution. The killing ability of CBZ@Lipo to cancer cells was significantly lower comparing to that of CBZ solution, which could be attributed to the slow release of CBZ from the liposomes. However, CBZ@Lipo could induce an obvious apoptosis of the cancer cells at low concentration. Furthermore, CBZ@Lipo exhibited an expressively enhanced tumor growth inhibition effect comparing to CBZ solution. More importantly, CBZ@Lipo showed an obviously higher biosafety proved by lower hemolysis probability, stable body weight of mice during the whole experiment and no obvious lesion in histology analysis. Our work provided a useful reference of the formulation of CBZ, which had potential for greater clinical application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Asian journal of pharmaceutical sciences - 14(2019), 6 vom: 14. Nov., Seite 658-667 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yin, Xiaoyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apoptosis |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ajps.2018.10.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30696810X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30696810X | ||
| 003 | DE-627 | ||
| 005 | 20231225124532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajps.2018.10.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1023.xml |
| 035 | |a (DE-627)NLM30696810X | ||
| 035 | |a (NLM)32104492 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yin, Xiaoyi |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2018 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. | ||
| 520 | |a The potential side effects of cabazitaxel (CBZ) in the field of cancer treatment have become a great limitation to its further clinical application. Liposomal delivery is a well-established approach to increase the therapeutic index of hydrophobic drugs. In this study, a PEG-modified liposome was developed for efficiently encapsulating CBZ, thus enhancing its specific tumor inhibition effect and reducing the systemic toxicity. It was found that the loading efficiency of CBZ into the liposome could be improved with the increase of lipophilic materials, as it could be over 80% under the weight ratio of 20:1 (total lipid: CBZ). The diameter of CBZ loaded liposome (CBZLipo) was ∼100 nm. And the liposome suspending in aqueous medium was stable at 4 °C for at least one month, according to the change of its size distribution. The killing ability of CBZ@Lipo to cancer cells was significantly lower comparing to that of CBZ solution, which could be attributed to the slow release of CBZ from the liposomes. However, CBZ@Lipo could induce an obvious apoptosis of the cancer cells at low concentration. Furthermore, CBZ@Lipo exhibited an expressively enhanced tumor growth inhibition effect comparing to CBZ solution. More importantly, CBZ@Lipo showed an obviously higher biosafety proved by lower hemolysis probability, stable body weight of mice during the whole experiment and no obvious lesion in histology analysis. Our work provided a useful reference of the formulation of CBZ, which had potential for greater clinical application | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Biosafety | |
| 650 | 4 | |a Cabazitaxel | |
| 650 | 4 | |a Liposome | |
| 650 | 4 | |a Stability | |
| 700 | 1 | |a Luo, Lihua |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Chunqi |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Mengshi |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Xiaoling |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yichao |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Yongzhong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Dawei |e verfasserin |4 aut | |
| 700 | 1 | |a You, Jian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Asian journal of pharmaceutical sciences |d 2017 |g 14(2019), 6 vom: 14. Nov., Seite 658-667 |w (DE-627)NLM306966247 |x 2221-285X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:6 |g day:14 |g month:11 |g pages:658-667 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajps.2018.10.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 6 |b 14 |c 11 |h 658-667 | ||